USING A COMBINATION OF PERINDOPRIL, INDAPAMIDE AND ROSUVASTATIN IN THE TREATMENT OF PATIENTS WITH HYPERTENSION AND DYSLIPIDEMIA

Aim. To study the antihypertensive and hypolipidemic effect of a group of drugs including perindopril,rosuvastatin and fixed-dose combination of perindopril and indapamide, in ambulatory patients with hypertension and dyslipidemia.

Material and methods. Analysis of the medical data of patients treated with perindopril, indapamide and rosuvastatin in the multicenter, non-interventional study (SYNERGY) was performed. Patients had a diagnosis of hypertension and dyslipidemia, determined in routine clinical practice. Therapy was prescribed to patients in various dosing regimens. The data of anamnesis, physical status, blood pressure measurements, lipid levels were taken from the patient's medical records. The safety assessment was also performed. The duration of follow-up was 8 weeks.

Results. A total of 1383 patients were included into the analysis, 53.5% (n=740) of women and 46.5% (n=643) of men. The average age was 55.8 years. 914 patients (66.1%) had previously received antihypertensive therapy, and 439 (31.7%) had previously received lipid-lowering therapy. A significant reduction in the levels of systolic (SBP), diastolic BP (DBP), and low-density lipoprotein cholesterol (LDL-c) was found at the end of the study in all study groups (p<0.05). This demonstrated an adequate antihypertensive and lipid-lowering effect of all treatment regimens. The mean decrease in SBP in treatment groups ranged from 14.3 to 36.2 mm Hg; the mean decrease in DBP – from 3.3 to 22.2 mm Hg. The maximum decrease in SBP was found in the group of perindopril + indapamide + rosuvastatin (PIR) 8 + 2.5 + 20 mg (36.2±12.3 mm Hg); the maximum decrease in DBP – in the group of perindopril + rosuvastatin 8 + 10 mg. The mean decrease in LDL-c level due to the combined treatment with perindopril, indapamide and rosuvastatin ranged from 0.62 mmol/L in PIR groups 2 + 0.625 + 5 mg and 8 + 2.5 + 5 mg to 1.78 mmol/L in PIR group 8 + 2.5 + 20 mg. Three of 1,383 patients reported adverse events after 4 weeks of treatment, while 13 patients – at the end of the study.

Conclusion. PIR therapy resulted in a significant reduction in blood pressure in all treatment groups compared with baseline levels. A dose-dependent reduction in SBP and LDL-c levels was found in all treatment groups. The tolerability of all treatment regimens was good. 

1. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19•2 million participants. Lancet. 2016;387(10026): 1377-96.

2. CollinsD.R., TompsonA.C., Onakpoya I.J., et al. Global cardiovascularrisk assessmentin the primary prevention of cardiovascular disease in adults: systematic review of systematic reviews. BMJ Open. 2017;7(3):e013650.

3. Cardiovascular prevention. Nationalrecommendations. Kardiovaskuljarnaja Terapija i Profilaktika. 2011; 10 (6) suppl 2: 3-64. (In Russ.) [Кардиоваскулярная профилактика.Национальные рекомендации. Кардиоваскулярная Терапия и Профилактика. 2011;10(6) приложение 2:3-64].

4. Benjamin E.J., Blaha M.J., Chiuve S.E., et al.Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017;135:e146-e603.

5. Olsen M.H.,Angell S.Y.,Asma S., et al.Acallto action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet. 2016;388(10060):2665-712.

6. Drapkina O.M., on behalf of SYNERGY researchers. Combination Therapy of High-Risk Patients in Real Clinical Practice. Results of SYNERGY Study. Part 1. Antihypertensive Branch. Rational Pharmacotherapy inCardiology.2017;13(2):155-63. (InRuss). [ДрапкинаО.М., от имени исследователей СИНЕРГИЯ. Комбинированная терапия пациентов высокого риска в условиях реальной клинической практики. Результатыисследования СИНЕРГИЯ.Часть 1.Антигипертензивная ветвь. Рациональная Фармакотерапия в Кардиологии. 2017;13(2):155-63].

7. Collins R., Reith C., Emberson J., et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532-61.

8. Emberson J., Whincup P., Morris R. et al. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J. 2004;25(6):484-91.

9. Holzgreve H., Risler T., Trenkwalder P. Efficacy and tolerability of the perindopril/indapamide combination therapy for hypertension: the PRIMUS study. Curr Med Res Opin. 2006;22(9):1849-58.

10. Toth K.Antihypertensive efficacy oftriple combination perindopril/indapamide plus amlodipine in highrisk hypertensives:results ofthe PIANIST study (Perindopril-Indapamide plusAmlodipiNe in high rISkhyperTensive patients). Am J Cardiovasc Drugs. 2014;14(2):137-45.

11. Drapkina O.M., Eliashevich S.O. Efficacy and Safety of Rosuvastatin in Patients ofDifferent Risk Groups of Developing Cardiovascular Diseases. Kardiologiia. 2015;55(2):72-81. (In Russ.) [Драпкина О.М., ЕлиашевичС.О.Эффективность и безопасность розувастатинa у пациентов различных групп сердечно-сосудистого риска. Кардиология. 2015;55(2):72-81].

12. O'Keefe J.H., Carter M.D., Lavie C.J., BellD.S. The gravity ofJUPITER (Justification forthe Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin). Postgrad Med. 2009 May;121(3):113-8.

13. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to PreventHeart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-97.

14. Sever P.S., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average orlower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA). Lancet. 2003;361(9364):1149-58.